thalidomide has been researched along with Sensitivity and Specificity in 31 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide, which inhibits angiogenesis in certain tumor types, reduced extravasation of a macromolecular contrast medium (MMCM) in a human breast cancer model as assayed by MMCM-enhanced dynamic magnetic resonance imaging (MRI) and fluorescence microscopy in the same tumors." | 7.75 | Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers. ( Brasch, RC; Chaopathomkul, B; Cyran, CC; Fu, Y; McDonald, DM; Rogut, VS; Sennino, B; Shames, DM; Wendland, MF, 2009) |
| "This article describes, for the first time, a highly sensitive and specific enzyme-linked immunosorbent assay (ELISA) for therapeutic monitoring and pharmacokinetic studies of lenalidomide (LND), the potent drug for treatment of multiple myeloma (MM)." | 3.80 | A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide. ( Abuhejail, RM; Alzoman, NZ; Darwish, IA, 2014) |
| " Inclusion criteria were diagnosis of stage III multiple myeloma and clinical indication for therapeutical administration of bortezomib or lenalidomide." | 3.76 | Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results. ( Brodoefel, H; Claussen, CD; Fenchel, M; Horger, M; Konaktchieva, M; Kraus, S; Weisel, K, 2010) |
| "Thalidomide, which inhibits angiogenesis in certain tumor types, reduced extravasation of a macromolecular contrast medium (MMCM) in a human breast cancer model as assayed by MMCM-enhanced dynamic magnetic resonance imaging (MRI) and fluorescence microscopy in the same tumors." | 3.75 | Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers. ( Brasch, RC; Chaopathomkul, B; Cyran, CC; Fu, Y; McDonald, DM; Rogut, VS; Sennino, B; Shames, DM; Wendland, MF, 2009) |
| "In 36 multiple myeloma (MM) patients, we measured serial changes in iFLC and M-protein after start of treatment." | 2.79 | Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. ( Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT, 2014) |
| "Thalidomide was first introduced to the market in Germany under the brand name of Contergan in 1956, as a non-barbiturate hypnotic, advocated to ensure a good nights sleep and to prevent morning sickness in pregnancy." | 2.41 | Mechanisms of action and potential therapeutic uses of thalidomide. ( Chabner, BA; Mujagić, H; Mujagić, Z, 2002) |
| "Multiple myeloma is a malignant hematological disorder of the mature B-cell lymphocytes originating in the bone marrow." | 1.43 | Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography. ( Bier, G; Fritz, J; Horger, M; Ioanoviciu, SD; Kum, S; Schabel, C; Weisel, K, 2016) |
| "Pomalidomide was recently approved by the United States Food and Drug Administration for the treatment of patients with relapsed or refractory multiple myeloma who have received at least two prior therapies." | 1.40 | Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. ( Byrd, JC; Chen, CS; Hofmeister, CC; Jiang, Y; Johnson, AJ; Kolli, S; Phelps, MA; Rozewski, DM; Wang, J; Wu, CH; Yang, X, 2014) |
| "Pomalidomide is a second generation IMiD (immunomodulatory agent) that has recently been granted approval by the Food and Drug Administration for treatment of relapsed multiple myeloma after prior treatment with two antimyeloma agents, including lenalidomide and bortezomib." | 1.40 | A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. ( Aleman, K; Figg, WD; Peer, CJ; Polizzotto, MN; Roth, J; Shahbazi, S; Uldrick, TS; Wyvill, KM; Yarchoan, R; Zeldis, JB, 2014) |
| "Thalidomide was extracted from human serum (100 μL), cells (2." | 1.38 | Development, validation and application of a sensitive LC-MS/MS method for the quantification of thalidomide in human serum, cells and cell culture medium. ( Clynes, M; Meiller, J; O'Connor, R; O'Gorman, P; Pedersen, K; Rajpal, R; Roche, S; Sewell, L, 2012) |
| "Thalidomide was approved for the treatment of relapsed or refractory multiple myeloma (MM) as an orphan drug in Japan." | 1.35 | A new method for determination of both thalidomide enantiomers using HPLC systems. ( Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Sakurada, K; Sembongi, K; Tanaka, M, 2008) |
| "Thalidomide was monitored by ultraviolet detector at 220 nm and it gave a linear response as a function of concentration over 0." | 1.33 | Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat. ( Chan, E; Chan, SY; Duan, W; Goh, BC; Ho, PC; Hu, Z; Yang, X; Zhou, S, 2005) |
| "To evaluate the patterns of birth defects associated with diabetic embryopathy, a sensitivity-specificity analysis was performed on 4929 infants with major defects ascertained by the population-based Metropolitan Atlanta Congenital Defects Program between 1968 and 1980." | 1.28 | Clinical-epidemiologic assessment of pattern of birth defects associated with human teratogens: application to diabetic embryopathy. ( Becerra, JE; Cordero, JF; Erickson, JD; Khoury, MJ, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.23) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 15 (48.39) | 29.6817 |
| 2010's | 14 (45.16) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Jiang, F | 1 |
| Peng, X | 1 |
| Cai, D | 1 |
| Wen, D | 1 |
| Liu, Y | 2 |
| Zhi, M | 1 |
| Chen, J | 1 |
| Hu, P | 1 |
| Wang, X | 1 |
| Gao, Y | 1 |
| Huang, M | 1 |
| Gao, X | 2 |
| Zhong, G | 1 |
| Winiczenko, R | 1 |
| Górnicki, K | 1 |
| Kaleta, A | 1 |
| Janaszek-Mańkowska, M | 1 |
| Khan, ZA | 1 |
| Singh, C | 1 |
| Khan, T | 1 |
| Ganguly, M | 1 |
| Bradsher, C | 1 |
| Goodwin, P | 1 |
| Petty, JT | 1 |
| Sandau, C | 1 |
| Bove, DG | 1 |
| Marsaa, K | 1 |
| Bekkelund, CS | 1 |
| Lindholm, MG | 1 |
| Salazar, J | 1 |
| Bermúdez, V | 1 |
| Olivar, LC | 1 |
| Torres, W | 1 |
| Palmar, J | 1 |
| Añez, R | 1 |
| Ordoñez, MG | 1 |
| Rivas, JR | 1 |
| Martínez, MS | 1 |
| Hernández, JD | 1 |
| Graterol, M | 1 |
| Rojas, J | 1 |
| Mubarak, Z | 1 |
| Humaira, A | 1 |
| Gani, BA | 1 |
| Muchlisin, ZA | 1 |
| Gremillet, C | 1 |
| Jakobsson, JG | 1 |
| Gomila, A | 1 |
| Shaw, E | 1 |
| Carratalà, J | 1 |
| Leibovici, L | 1 |
| Tebé, C | 1 |
| Wiegand, I | 1 |
| Vallejo-Torres, L | 1 |
| Vigo, JM | 1 |
| Morris, S | 1 |
| Stoddart, M | 1 |
| Grier, S | 1 |
| Vank, C | 1 |
| Cuperus, N | 1 |
| Van den Heuvel, L | 1 |
| Eliakim-Raz, N | 1 |
| Vuong, C | 1 |
| MacGowan, A | 1 |
| Addy, I | 1 |
| Pujol, M | 1 |
| Cobb, A | 1 |
| Rieger, E | 1 |
| Bell, J | 1 |
| Mallik, S | 1 |
| Zhao, Z | 1 |
| Szécsényi, Á | 1 |
| Li, G | 1 |
| Gascon, J | 1 |
| Pidko, EA | 1 |
| Zhang, GR | 1 |
| Wolker, T | 1 |
| Sandbeck, DJS | 1 |
| Munoz, M | 1 |
| Mayrhofer, KJJ | 1 |
| Cherevko, S | 1 |
| Etzold, BJM | 1 |
| Lukashuk, L | 1 |
| Yigit, N | 1 |
| Rameshan, R | 1 |
| Kolar, E | 1 |
| Teschner, D | 1 |
| Hävecker, M | 1 |
| Knop-Gericke, A | 1 |
| Schlögl, R | 1 |
| Föttinger, K | 1 |
| Rupprechter, G | 1 |
| Franconieri, F | 1 |
| Deshayes, S | 1 |
| de Boysson, H | 1 |
| Trad, S | 1 |
| Martin Silva, N | 1 |
| Terrier, B | 1 |
| Bienvenu, B | 1 |
| Galateau-Sallé, F | 1 |
| Emile, JF | 1 |
| Johnson, AC | 1 |
| Aouba, A | 1 |
| Vogt, TJ | 1 |
| Gevensleben, H | 1 |
| Dietrich, J | 1 |
| Kristiansen, G | 1 |
| Bootz, F | 1 |
| Landsberg, J | 1 |
| Goltz, D | 1 |
| Dietrich, D | 1 |
| Idorn, M | 1 |
| Skadborg, SK | 1 |
| Kellermann, L | 1 |
| Halldórsdóttir, HR | 1 |
| Holmen Olofsson, G | 1 |
| Met, Ö | 1 |
| Thor Straten, P | 1 |
| Johnson, LE | 1 |
| Brockstedt, D | 1 |
| Leong, M | 1 |
| Lauer, P | 1 |
| Theisen, E | 1 |
| Sauer, JD | 1 |
| McNeel, DG | 1 |
| Morandi, F | 1 |
| Marimpietri, D | 1 |
| Horenstein, AL | 1 |
| Bolzoni, M | 1 |
| Toscani, D | 1 |
| Costa, F | 1 |
| Castella, B | 1 |
| Faini, AC | 1 |
| Massaia, M | 1 |
| Pistoia, V | 1 |
| Giuliani, N | 1 |
| Malavasi, F | 1 |
| Qiu, J | 1 |
| Peng, S | 1 |
| Yang, A | 1 |
| Ma, Y | 1 |
| Han, L | 1 |
| Cheng, MA | 1 |
| Farmer, E | 1 |
| Hung, CF | 1 |
| Wu, TC | 1 |
| Modak, S | 1 |
| Le Luduec, JB | 1 |
| Cheung, IY | 1 |
| Goldman, DA | 1 |
| Ostrovnaya, I | 1 |
| Doubrovina, E | 1 |
| Basu, E | 1 |
| Kushner, BH | 1 |
| Kramer, K | 1 |
| Roberts, SS | 1 |
| O'Reilly, RJ | 1 |
| Cheung, NV | 1 |
| Hsu, KC | 1 |
| Salgarello, T | 1 |
| Giudiceandrea, A | 1 |
| Calandriello, L | 1 |
| Marangoni, D | 1 |
| Colotto, A | 1 |
| Caporossi, A | 1 |
| Falsini, B | 1 |
| Lefrançois, P | 1 |
| Xie, P | 1 |
| Wang, L | 2 |
| Tetzlaff, MT | 1 |
| Moreau, L | 1 |
| Watters, AK | 1 |
| Netchiporouk, E | 1 |
| Provost, N | 1 |
| Gilbert, M | 1 |
| Ni, X | 1 |
| Sasseville, D | 1 |
| Wheeler, DA | 1 |
| Duvic, M | 1 |
| Litvinov, IV | 1 |
| O'Connor, BJ | 1 |
| Fryda, NJ | 1 |
| Ranglack, DH | 1 |
| Yang, Y | 2 |
| Yang, J | 1 |
| Zhang, X | 2 |
| Grün, AL | 1 |
| Emmerling, C | 1 |
| Aumeeruddy-Elalfi, Z | 1 |
| Ismaël, IS | 1 |
| Hosenally, M | 1 |
| Zengin, G | 1 |
| Mahomoodally, MF | 1 |
| Dotsenko, A | 1 |
| Gusakov, A | 1 |
| Rozhkova, A | 1 |
| Sinitsyna, O | 1 |
| Shashkov, I | 1 |
| Sinitsyn, A | 1 |
| Hong, CE | 1 |
| Kim, JU | 1 |
| Lee, JW | 1 |
| Lee, SW | 1 |
| Jo, IH | 1 |
| Pandiyarajan, S | 1 |
| Premasudha, P | 1 |
| Kadirvelu, K | 1 |
| Wang, B | 1 |
| Luo, L | 1 |
| Wang, D | 1 |
| Ding, R | 1 |
| Hong, J | 1 |
| Caviezel, D | 1 |
| Maissen, S | 1 |
| Niess, JH | 1 |
| Kiss, C | 1 |
| Hruz, P | 1 |
| Pockes, S | 1 |
| Wifling, D | 1 |
| Keller, M | 1 |
| Buschauer, A | 1 |
| Elz, S | 1 |
| Santos, AF | 1 |
| Ferreira, IP | 1 |
| Pinheiro, CB | 1 |
| Santos, VG | 1 |
| Lopes, MTP | 1 |
| Teixeira, LR | 1 |
| Rocha, WR | 1 |
| Rodrigues, GLS | 1 |
| Beraldo, H | 1 |
| Lohar, S | 1 |
| Dhara, K | 1 |
| Roy, P | 1 |
| Sinha Babu, SP | 1 |
| Chattopadhyay, P | 1 |
| Sukwong, P | 1 |
| Sunwoo, IY | 1 |
| Lee, MJ | 1 |
| Ra, CH | 1 |
| Jeong, GT | 1 |
| Kim, SK | 2 |
| Huvinen, E | 1 |
| Eriksson, JG | 1 |
| Stach-Lempinen, B | 1 |
| Tiitinen, A | 1 |
| Koivusalo, SB | 1 |
| Malhotra, M | 1 |
| Suresh, S | 1 |
| Garg, A | 1 |
| Wei, L | 1 |
| Jiang, Y | 3 |
| Zhou, W | 1 |
| Liu, S | 1 |
| Rausch-Fan, X | 1 |
| Liu, Z | 1 |
| Marques, WL | 1 |
| van der Woude, LN | 1 |
| Luttik, MAH | 1 |
| van den Broek, M | 1 |
| Nijenhuis, JM | 1 |
| Pronk, JT | 1 |
| van Maris, AJA | 1 |
| Mans, R | 1 |
| Gombert, AK | 1 |
| Xu, A | 1 |
| Sun, J | 1 |
| Li, J | 1 |
| Chen, W | 2 |
| Zheng, R | 1 |
| Han, Z | 1 |
| Ji, L | 1 |
| Shen, WQ | 1 |
| Bao, LP | 1 |
| Hu, SF | 1 |
| Gao, XJ | 1 |
| Xie, YP | 1 |
| Gao, XF | 1 |
| Huang, WH | 1 |
| Lu, X | 1 |
| Gostin, PF | 1 |
| Addison, O | 1 |
| Morrell, AP | 1 |
| Zhang, Y | 2 |
| Cook, AJMC | 1 |
| Liens, A | 1 |
| Stoica, M | 1 |
| Ignatyev, K | 1 |
| Street, SR | 1 |
| Wu, J | 1 |
| Chiu, YL | 1 |
| Davenport, AJ | 1 |
| Qiu, Z | 1 |
| Shu, J | 1 |
| Tang, D | 1 |
| Zhang, J | 3 |
| Huang, K | 1 |
| Wai, H | 1 |
| Du, K | 1 |
| Anesini, J | 1 |
| Kim, WS | 1 |
| Eastman, A | 1 |
| Micalizio, GC | 1 |
| Liang, JH | 1 |
| Huo, XK | 1 |
| Cheng, ZB | 1 |
| Sun, CP | 1 |
| Zhao, JC | 1 |
| Kang, XH | 1 |
| Zhang, TY | 1 |
| Chen, ZJ | 1 |
| Yang, TM | 1 |
| Wu, YY | 1 |
| Deng, XP | 1 |
| Zhang, YX | 1 |
| Salem, HF | 1 |
| Kharshoum, RM | 1 |
| Abou-Taleb, HA | 1 |
| AbouTaleb, HA | 1 |
| AbouElhassan, KM | 1 |
| Ohata, C | 1 |
| Ohyama, B | 1 |
| Kuwahara, F | 1 |
| Katayama, E | 1 |
| Nakama, T | 1 |
| Kobayashi, S | 1 |
| Kashiwagi, T | 1 |
| Kimura, J | 1 |
| Lin, JD | 1 |
| Liou, MJ | 1 |
| Hsu, HL | 1 |
| Leong, KK | 1 |
| Chen, YT | 1 |
| Wang, YR | 1 |
| Hung, WS | 1 |
| Lee, HY | 1 |
| Tsai, HJ | 1 |
| Tseng, CP | 1 |
| Alten, B | 1 |
| Yesiltepe, M | 1 |
| Bayraktar, E | 1 |
| Tas, ST | 1 |
| Gocmen, AY | 1 |
| Kursungoz, C | 1 |
| Martinez, A | 1 |
| Sara, Y | 1 |
| Huang, S | 2 |
| Adams, E | 1 |
| Van Schepdael, A | 1 |
| Wang, Q | 1 |
| Chung, CY | 1 |
| Yang, W | 1 |
| Yang, G | 1 |
| Chough, S | 1 |
| Chen, Y | 1 |
| Yin, B | 1 |
| Bhattacharya, R | 1 |
| Hu, Y | 1 |
| Saeui, CT | 1 |
| Yarema, KJ | 1 |
| Betenbaugh, MJ | 1 |
| Zhang, H | 1 |
| Patik, JC | 1 |
| Tucker, WJ | 1 |
| Curtis, BM | 1 |
| Nelson, MD | 1 |
| Nasirian, A | 1 |
| Park, S | 1 |
| Brothers, RM | 1 |
| Dohlmann, TL | 1 |
| Hindsø, M | 1 |
| Dela, F | 1 |
| Helge, JW | 1 |
| Larsen, S | 1 |
| Gayani, B | 1 |
| Dilhari, A | 1 |
| Wijesinghe, GK | 1 |
| Kumarage, S | 1 |
| Abayaweera, G | 1 |
| Samarakoon, SR | 1 |
| Perera, IC | 1 |
| Kottegoda, N | 1 |
| Weerasekera, MM | 1 |
| Nardi, MV | 1 |
| Timpel, M | 1 |
| Ligorio, G | 1 |
| Zorn Morales, N | 1 |
| Chiappini, A | 1 |
| Toccoli, T | 1 |
| Verucchi, R | 1 |
| Ceccato, R | 1 |
| Pasquali, L | 1 |
| List-Kratochvil, EJW | 1 |
| Quaranta, A | 1 |
| Dirè, S | 1 |
| Heo, K | 1 |
| Jo, SH | 1 |
| Shim, J | 1 |
| Kang, DH | 1 |
| Kim, JH | 1 |
| Park, JH | 1 |
| Akhtar, N | 1 |
| Saha, A | 1 |
| Kumar, V | 1 |
| Pradhan, N | 1 |
| Panda, S | 1 |
| Morla, S | 1 |
| Kumar, S | 1 |
| Manna, D | 1 |
| Wang, H | 1 |
| Xu, E | 1 |
| Yu, S | 1 |
| Li, D | 1 |
| Quan, J | 1 |
| Xu, L | 1 |
| Saslow, SA | 1 |
| Um, W | 1 |
| Pearce, CI | 1 |
| Bowden, ME | 1 |
| Engelhard, MH | 1 |
| Lukens, WL | 1 |
| Kim, DS | 1 |
| Schweiger, MJ | 1 |
| Kruger, AA | 1 |
| Adair, LS | 1 |
| Kuzawa, C | 1 |
| McDade, T | 1 |
| Carba, DB | 1 |
| Borja, JB | 1 |
| Liang, X | 2 |
| Song, W | 1 |
| Wang, K | 1 |
| Zhang, B | 1 |
| Peele, ME | 1 |
| Luo, HR | 1 |
| Chen, ZY | 1 |
| Fei, JJ | 1 |
| Du, ZJ | 1 |
| Yi, KJ | 1 |
| Im, WT | 1 |
| Kim, DW | 1 |
| Ji, X | 1 |
| Zhang, C | 1 |
| Xu, Z | 1 |
| Ding, Y | 1 |
| Song, Q | 1 |
| Li, B | 2 |
| Zhao, H | 1 |
| Lee, DW | 1 |
| Lee, H | 1 |
| Kwon, BO | 1 |
| Khim, JS | 1 |
| Yim, UH | 1 |
| Park, H | 1 |
| Park, B | 1 |
| Choi, IG | 1 |
| Kim, BS | 1 |
| Kim, JJ | 1 |
| Wang, JJ | 1 |
| Chen, Q | 1 |
| Li, YZ | 1 |
| Sakai, M | 1 |
| Yamaguchi, M | 1 |
| Nagao, Y | 1 |
| Kawachi, N | 1 |
| Kikuchi, M | 1 |
| Torikai, K | 1 |
| Kamiya, T | 1 |
| Takeda, S | 1 |
| Watanabe, S | 1 |
| Takahashi, T | 1 |
| Arakawa, K | 1 |
| Nakano, T | 1 |
| Rufo, S | 1 |
| Continentino, MA | 1 |
| Nikolaou, V | 1 |
| Plass, F | 1 |
| Planchat, A | 1 |
| Charisiadis, A | 1 |
| Charalambidis, G | 1 |
| Angaridis, PA | 1 |
| Kahnt, A | 1 |
| Odobel, F | 1 |
| Coutsolelos, AG | 1 |
| Fuentes, I | 1 |
| García-Mendiola, T | 1 |
| Sato, S | 1 |
| Pita, M | 1 |
| Nakamura, H | 1 |
| Lorenzo, E | 1 |
| Teixidor, F | 1 |
| Marques, F | 1 |
| Viñas, C | 1 |
| Liu, F | 1 |
| Qi, P | 1 |
| Zhang, L | 1 |
| Wang, J | 1 |
| Rozewski, DM | 1 |
| Kolli, S | 1 |
| Wu, CH | 1 |
| Chen, CS | 1 |
| Yang, X | 2 |
| Hofmeister, CC | 1 |
| Byrd, JC | 1 |
| Johnson, AJ | 1 |
| Phelps, MA | 1 |
| Alzoman, NZ | 1 |
| Darwish, IA | 1 |
| Abuhejail, RM | 1 |
| Veeraraghavan, S | 1 |
| Thappali, S | 1 |
| Viswanadha, S | 1 |
| Nalla, S | 1 |
| Chennupati, S | 1 |
| Golla, M | 1 |
| Vakkalanka, S | 1 |
| Rangasamy, M | 1 |
| Shahbazi, S | 1 |
| Peer, CJ | 1 |
| Polizzotto, MN | 1 |
| Uldrick, TS | 1 |
| Roth, J | 1 |
| Wyvill, KM | 1 |
| Aleman, K | 1 |
| Zeldis, JB | 1 |
| Yarchoan, R | 1 |
| Figg, WD | 2 |
| Hansen, CT | 1 |
| Pedersen, PT | 1 |
| Nielsen, LC | 1 |
| Abildgaard, N | 1 |
| Messingerová, L | 1 |
| Jonášová, A | 1 |
| Barančik, M | 1 |
| Poleková, L | 1 |
| Šereš, M | 1 |
| Gibalová, L | 1 |
| Breier, A | 1 |
| Sulová, Z | 1 |
| Schabel, C | 1 |
| Horger, M | 2 |
| Kum, S | 1 |
| Weisel, K | 2 |
| Fritz, J | 1 |
| Ioanoviciu, SD | 1 |
| Bier, G | 1 |
| Cyran, CC | 1 |
| Sennino, B | 1 |
| Chaopathomkul, B | 1 |
| Fu, Y | 1 |
| Rogut, VS | 1 |
| Shames, DM | 1 |
| Wendland, MF | 1 |
| McDonald, DM | 1 |
| Brasch, RC | 1 |
| Tang, AN | 1 |
| Wang, XN | 1 |
| Ding, GS | 1 |
| Yan, XP | 1 |
| Zhou, J | 1 |
| Zheng, W | 1 |
| Cao, L | 1 |
| Liu, M | 1 |
| Han, F | 1 |
| Li, A | 1 |
| Fenchel, M | 1 |
| Konaktchieva, M | 1 |
| Kraus, S | 1 |
| Brodoefel, H | 1 |
| Claussen, CD | 1 |
| Rajpal, R | 2 |
| Dowling, P | 1 |
| Meiller, J | 2 |
| Clarke, C | 1 |
| Murphy, WG | 1 |
| O'Connor, R | 2 |
| Kell, M | 1 |
| Mitsiades, C | 1 |
| Richardson, P | 1 |
| Anderson, KC | 1 |
| Clynes, M | 2 |
| O'Gorman, P | 2 |
| Roche, S | 1 |
| Sewell, L | 1 |
| Pedersen, K | 1 |
| Hasnain, MS | 1 |
| Rao, S | 1 |
| Singh, MK | 1 |
| Vig, N | 1 |
| Gupta, A | 1 |
| Ansari, A | 1 |
| Sen, P | 1 |
| Joshi, P | 1 |
| Ansari, SA | 1 |
| Boccadoro, M | 1 |
| Palumbo, A | 1 |
| Zhou, S | 2 |
| Li, Y | 1 |
| Kestell, P | 1 |
| Paxton, JW | 1 |
| Tohnya, TM | 1 |
| Hwang, K | 1 |
| Lepper, ER | 1 |
| Fine, HA | 1 |
| Dahut, WL | 1 |
| Venitz, J | 1 |
| Sparreboom, A | 1 |
| Huang, YJ | 1 |
| Liao, JF | 1 |
| Tsai, TH | 1 |
| Pigott, A | 1 |
| Casson, D | 1 |
| Hu, Z | 1 |
| Chan, SY | 1 |
| Ho, PC | 1 |
| Chan, E | 1 |
| Duan, W | 1 |
| Goh, BC | 1 |
| Calligaris, L | 1 |
| Marchetti, F | 1 |
| Ventura, A | 1 |
| Sembongi, K | 1 |
| Tanaka, M | 1 |
| Sakurada, K | 1 |
| Kobayashi, M | 1 |
| Itagaki, S | 1 |
| Hirano, T | 1 |
| Iseki, K | 1 |
| Toraño, JS | 1 |
| Verbon, A | 1 |
| Guchelaar, HJ | 1 |
| Oliver, SJ | 1 |
| Schoetz, G | 1 |
| Trapp, O | 1 |
| Schurig, V | 1 |
| Teo, SK | 1 |
| Chandula, RS | 1 |
| Harden, JL | 1 |
| Stirling, DI | 1 |
| Thomas, SD | 1 |
| Mujagić, H | 1 |
| Chabner, BA | 1 |
| Mujagić, Z | 1 |
| Khoury, MJ | 1 |
| Becerra, JE | 1 |
| Cordero, JF | 1 |
| Erickson, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multidose Phase I Study of Oral CC5013, a Thalidomide Derivative, in Patients With Refractory Metastatic Cancer[NCT00031941] | Phase 1 | 0 participants | Interventional | 2002-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for thalidomide and Sensitivity and Specificity
| Article | Year |
|---|---|
New developments and treatment in multiple myeloma: new drugs in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Cysteine Endopeptidases; Diphosphonates; Female; Humans; Male; Multienzyme Co | 2002 |
The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Female; Humans; Immunity, Cellular; Immun | 2000 |
Mechanisms of action and potential therapeutic uses of thalidomide.
Topics: Clinical Trials as Topic; Humans; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Risk Asses | 2002 |
4 trials available for thalidomide and Sensitivity and Specificity
| Article | Year |
|---|---|
Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosp | 2018 |
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2014 |
Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.
Topics: Adult; Aged; Anemia, Macrocytic; Biomarkers; Blood Proteins; Chromosome Deletion; Chromosomes, Human | 2015 |
Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry.
Topics: Adult; Calibration; Chromatography, Liquid; Double-Blind Method; HIV Seropositivity; Humans; Male; M | 2002 |
24 other studies available for thalidomide and Sensitivity and Specificity
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
A validated LC-MS/MS method for the simultaneous determination of thalidomide and its two metabolites in human plasma: Application to a pharmacokinetic assay.
Topics: Chromatography, Liquid; Drug Stability; Humans; Linear Models; Male; Reproducibility of Results; Sen | 2018 |
Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.
Topics: Animals; Brain; Chromatography, Liquid; Immunologic Factors; Linear Models; Mice; Quality Control; R | 2014 |
A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide.
Topics: Animals; Cattle; Cloning, Molecular; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immune Sera; | 2014 |
Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Stability; Lenalidomide; Male; Purines; Quinazol | 2014 |
A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.
Topics: Biological Assay; Chromatography, High Pressure Liquid; Drug Stability; Fluorescence; Humans; Liquid | 2014 |
Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone and Bones; Bone Marro | 2016 |
Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Disease Models, Animal; Magnetic Resonance Imagi | 2009 |
On-line preconcentration and enantioseparation of thalidomide racemates by CEC with the hyphenation of octyl and norvancomycin monoliths.
Topics: Acetonitriles; Capillary Electrochromatography; Humans; Polytetrafluoroethylene; Reproducibility of | 2009 |
Antiangiogenic tumor treatment: noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Contrast Media; Image Enhancement; Image Interpr | 2010 |
Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results.
Topics: Aged; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Magnetic Res | 2010 |
A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Gene Expressi | 2011 |
Development, validation and application of a sensitive LC-MS/MS method for the quantification of thalidomide in human serum, cells and cell culture medium.
Topics: Cell Extracts; Cell Line, Tumor; Chromatography, Liquid; Culture Media; Drug Stability; Humans; Liqu | 2012 |
Development and validation of LC-MS/MS method for the quantitation of lenalidomide in human plasma using Box-Behnken experimental design.
Topics: Angiogenesis Inhibitors; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Humans; | 2013 |
Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection.
Topics: Buffers; Caco-2 Cells; Calibration; Chromatography, High Pressure Liquid; Humans; Reproducibility of | 2003 |
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry.
Topics: Calibration; Chromatography, High Pressure Liquid; Humans; Lenalidomide; Mass Spectrometry; Reproduc | 2004 |
Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography.
Topics: Animals; Bile; Brain Chemistry; Chromatography, High Pressure Liquid; Male; Microdialysis; Rats; Rat | 2005 |
Thalidomide in Crohn disease.
Topics: Clinical Trials as Topic; Crohn Disease; Diagnosis, Differential; Dose-Response Relationship, Drug; | 2005 |
Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat.
Topics: Animals; Area Under Curve; Chromatography, High Pressure Liquid; Male; Rats; Rats, Sprague-Dawley; R | 2005 |
Intestinal plexiform neurofibromas.
Topics: Angiogenesis Inhibitors; Child; Diagnosis, Differential; Female; Humans; Ileal Neoplasms; Mesentery; | 2008 |
A new method for determination of both thalidomide enantiomers using HPLC systems.
Topics: Angiogenesis Inhibitors; Chromatography, High Pressure Liquid; Female; Humans; Molecular Structure; | 2008 |
Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection.
Topics: Blood Proteins; Chemical Precipitation; Chromatography, High Pressure Liquid; Drug Stability; Humans | 1999 |
Determination of the enantiomerization barrier of thalidomide by dynamic capillary electrokinetic chromatography.
Topics: beta-Cyclodextrins; Chromatography; Computer Simulation; Cyclodextrins; Hydrogen-Ion Concentration; | 2001 |
Clinical-epidemiologic assessment of pattern of birth defects associated with human teratogens: application to diabetic embryopathy.
Topics: Abnormalities, Drug-Induced; Congenital Abnormalities; Diabetes Mellitus, Type 1; Female; Georgia; H | 1989 |